Form 4: Director Cox Receives ANRO Stock Options

Alto Neuroscience Director Christopher Nixon Cox was granted 7,189 stock options in lieu of $85,000 in retainer fees, vesting quarterly throughout 2026.

Summary

• Christopher Nixon Cox, a Director of Alto Neuroscience, Inc. (ANRO), was granted 7,189 stock options on January 2, 2026.
• The options have an exercise price of $16.59 per share and are set to expire on January 1, 2036.
• This grant was made pursuant to the Issuer's Non-Employee Director Compensation Policy and is in lieu of $85,000 in retainer fees.
• The options vest quarterly throughout 2026, with 1,797 shares vesting on March 31, 2026, 1,797 shares on June 30, 2026, 1,798 shares on September 30, 2026, and 1,797 shares on December 31, 2026, all subject to continuous service.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options aligns director interests with shareholders, which is generally viewed favorably. However, it is a routine compensation event rather than a significant operational or financial announcement.

Positives

• Director compensation is structured with equity, aligning the director's financial interests with those of shareholders.
• The grant is part of a standard Non-Employee Director Compensation Policy, indicating a structured and transparent approach to corporate governance regarding director remuneration.

Risks

• The vesting of the options is contingent upon the reporting person's continuous service through each vesting date, meaning the options could be forfeited if service ceases.
• The ultimate value realized from these options is dependent on the future market performance of Alto Neuroscience, Inc.'s common stock.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the specified vesting schedule of the granted options, which extends through December 31, 2026.

Management Comments

• The option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $85,000.

Industry Context

The use of equity-based compensation for non-employee directors is a common practice in the biotechnology and pharmaceutical industries, aligning director incentives with long-term shareholder value creation. This practice is particularly prevalent in growth-oriented companies like Alto Neuroscience, which may seek to conserve cash while attracting and retaining experienced board members.

Comparison to Industry Standards

• Granting stock options to non-employee directors as part of their compensation package is a standard practice across many industries, including biotechnology. This approach is consistent with corporate governance best practices aimed at aligning director interests with those of shareholders.
• While specific comparable companies or projects are not detailed in this filing, the general structure of equity compensation for directors is widely adopted by peers in the pharmaceutical and neuroscience sectors, often involving a mix of stock options and restricted stock units.

Corporate Governance

Stakeholder Impact

• Shareholders: Interests are potentially better aligned with the director due to the equity-based compensation structure.
• Director (Christopher Nixon Cox): Receives equity compensation in lieu of cash, providing potential for future gains based on the company's stock performance, contingent on continued service.

Next Steps

• The vesting of 1,797 shares on March 31, 2026, subject to continuous service.
• The vesting of 1,797 shares on June 30, 2026, subject to continuous service.
• The vesting of 1,798 shares on September 30, 2026, subject to continuous service.
• The vesting of 1,797 shares on December 31, 2026, subject to continuous service.

Key Dates

Keywords

Alto Neuroscience, ANRO, Stock Options, Director Compensation, Equity Grant, SEC Form 4, Insider Transaction, Christopher Nixon Cox